Advances in the Medical Treatment of Clostridioides difficile Infection
Authors:
- 21 August 2025
- journal article
- review article
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 39 (4) , 629-651
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Oral Vancomycin for Prevention of Recurrent Clostridioides difficile InfectionJAMA Network Open, 2025
- Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative ReviewInfectious Diseases and Therapy, 2023
- Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United StatesInfectious Diseases and Therapy, 2021
- Molecular mechanisms of vancomycin resistanceProtein Science, 2020
- Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidenceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- A systematic review of the use of rifaximin for Clostridium difficile infectionsAnaerobe, 2019
- Fidaxomicin versus Vancomycin as a First‐Line Treatment for Clostridium difficile–Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic EvaluationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence countryEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyInfection, 2016
- Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in SpainEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015